Integrating ferroptosis and the tumor-immune gene mutations interface: a novel lenvatinib resistance prognostic signature with YWHAB-related immunotherapeutic correlates in hepatocellular carcinoma
Lenvatinib resistance represents a major clinical challenge in the treatment of hepatocellular carcinoma (HCC), necessitating the identification of strategies to overcome this issue. Although ferroptosis, a non-apoptotic cell death process, is implicated in the progression of HCC and the response to lenvatinib, the...